baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Aktienanleihe AMD 28.06.2024/ DE000VU8J582 /

5/10/2024 7:50:31 PM	Chg.-0.030	Bid9:59:55 PM	Ask9:59:55 PM	Underlying	Strike price	Expiration date	Option type
101.140EUR	-0.03%	- Bid Size: -	- Ask Size: -	Advanced Micro Devic...	110.00 USD	6/28/2024	Call

GlobeNewswire 5/9 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 5/9 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...

GlobeNewswire 5/9 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire 5/8 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...

GlobeNewswire 5/8 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...

GlobeNewswire 5/8 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...

GlobeNewswire 5/8 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

GlobeNewswire 5/8 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...

GlobeNewswire 5/7 Ocular Therapeutix™ Reports First Quarter 2024 Results

GlobeNewswire 5/7 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...

GlobeNewswire 5/7 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

GlobeNewswire 5/7 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5/6 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

GlobeNewswire 5/6 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...

GlobeNewswire 5/6 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...

GlobeNewswire 5/6 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

GlobeNewswire 5/6 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...

GlobeNewswire 5/3 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

GlobeNewswire 5/3 YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...

GlobeNewswire 5/2 Outlook Therapeutics® to Present at the Retina World Congress 2024

GlobeNewswire 5/2 Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology...

GlobeNewswire 5/2 YieldMax™ Launches Short TSLA Option Income Strategy ETF CRSH

GlobeNewswire 5/1 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...

GlobeNewswire 5/1 Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Mark...

TeleTrader 5/1 AI-related stocks plunge, Super Micro leads with 17% decline

BVT Aktienanleihe AMD 28.06.2024/ DE000VU8J582 /

If you wish to receive reply to your feedback, please provide your email address.